The GLP-1 Era – Redefining Obesity and Diabetes Through Data-Driven Metabolic Care
Few developments have generated as much excitement in modern medicine as GLP-1 receptor agonists. Originally developed for diabetes management, these therapies are now reshaping conversations around obesity, metabolic disease, cardiovascular risk reduction, and preventive healthcare.
This session examines how the emergence of GLP-1 therapies is changing the future of metabolic care.
The discussion features leading clinicians and experts involved in obesity management, diabetes care, gastroenterology, and clinical research.
Dr. Rakesh Kalapala, Director of Endoscopy and Consultant Gastroenterologist, brings extensive experience in metabolic disorders, digestive health, obesity-related complications, and advanced clinical interventions.
Dr. Maya Sharma, Vice President – Clinical Medical Research, contributes expertise in clinical development, therapeutic innovation, evidence generation, and emerging metabolic therapies.
Dr. Nava Vikas Jukanti, Chief and Senior Consultant Physician, provides frontline clinical perspectives on diabetes management, obesity treatment, and chronic disease prevention.
The session will explore how obesity is increasingly being recognized as a chronic biological disease rather than simply a lifestyle issue. Discussions will focus on the science of appetite regulation, insulin resistance, metabolic dysfunction, inflammation, and long-term weight management.
Speakers will examine the impact of GLP-1 therapies on diabetes outcomes, cardiovascular health, obesity treatment, healthcare economics, and patient behavior. The panel will also discuss challenges including affordability, accessibility, long-term sustainability, physician adoption, and patient education.
A key theme will be the role of data-driven metabolic care. Advances in continuous glucose monitoring, digital therapeutics, predictive analytics, and personalized health monitoring are creating opportunities for more precise interventions and improved patient outcomes.
For endocrinologists, physicians, healthcare leaders, pharmaceutical professionals, researchers, and policymakers, this session offers valuable insights into one of the most transformative developments in modern medicine.
As healthcare increasingly shifts toward prevention and metabolic optimization, GLP-1 therapies may represent the beginning of a much larger transformation in how chronic diseases are understood and managed.
